Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 16/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709792 | 0.91 | LPAR1 (0.60) | LPAR1TSHRLPAR2LPAR5LPAR3 | |
| SCHEMBL708091 | 0.85 | LPAR1 (0.69) | LPAR1LPAR2LPAR5LPAR3 | |
| SCHEMBL707256 | 0.83 | LPAR1 (0.74) | LPAR1LPAR2LPAR5LPAR3 | |
| SCHEMBL19438688 | 0.82 | TSHR (0.57) | LPAR1TSHRLPAR2PPARG | |
| SCHEMBL705695 | 0.81 | LPAR1 (0.81) | LPAR1LPAR2LPAR5LPAR3 | |
| SCHEMBL707389 | 0.76 | LPAR1 (0.64) | LPAR1LPAR2LPAR5LPAR3 | |
| SCHEMBL708221 | 0.75 | LPAR1 (0.76) | LPAR1LPAR2LPAR5LPAR3 | |
| SCHEMBL709277 | 0.74 | LPAR1 (0.75) | LPAR1LPAR2 | |
| SCHEMBL1284925 | 0.74 | LPAR1 (0.72) | LPAR1LPAR2LPAR5 | |
| SCHEMBL706127 | 0.73 | LPAR1 (0.82) | LPAR1LPAR2LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885TSHR 1995/4885MRGPRX4 102/4885 |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885TSHR 1995/4885MRGPRX4 102/4885 |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885TSHR 1995/4885MRGPRX4 102/4885 |
| US-20060148830-A1 | Lpa receptor antagonist | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885TSHR 1995/4885MRGPRX4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.